SG Americas Securities
AVTX icon

SG Americas Securities’s Avalo Therapeutics AVTX Stock Holding History

SG Americas Securities’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4
Closed -$17K – 2963
2021
Q4 		$17K Sell
4
-2
-33% -$12K ﹤0.01% 3270
2021
Q3 		$41K Buy
+6
New +$48.6K ﹤0.01% 3748
2020
Q3 		– Sell
-5
Closed -$41K – 2717
2020
Q2 		$41K Buy
+5
New +$36.3K ﹤0.01% 3559

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SG Americas Securities's AVTX Position: Q1 2022 in Review

SG Americas Securities sold out of Avalo Therapeutics (AVTX) in Q1 2022, closing a stake of 4 shares — an estimated $17K sold.

SG Americas Securities first reported a position in AVTX in Q2 2020 and held it in 3 quarters. The position peaked at $41K in Q3 2021. 65 funds tracked by Wall St. Rank hold AVTX as of Q1 2022.

  • SG Americas Securities reported no remaining Avalo Therapeutics position as of Q1 2022 after selling out during the quarter.
  • SG Americas Securities sold 4 Avalo Therapeutics shares in Q1 2022, an estimated $17K.
  • SG Americas Securities first reported a position in Avalo Therapeutics in Q2 2020 and held it in 3 quarters.
  • SG Americas Securities's Avalo Therapeutics position peaked at $41K in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2022.

Based on SG Americas Securities's 13F filing for Q1 2022, filed 29 Apr 2022.